Simponi golimumab regulatory update

EMA's CHMP issued a positive opinion recommending expanding the label of Simponi golimumab from Johnson & Johnson to include treatment of moderately to severely active ulcerative colitis (UC)

Read the full 286 word article

How to gain access

Continue reading with a
two-week free trial.